Subsequently, Bergantini et al. analyzed serial measurements of blood mucin-1/KL-6 in nintedanib-treated patients with IPF and showed that mucin-1/KL-6 levels might become stable over time (up to 12 months) following antifibrotic treatment and that changes in serial mucin-1/KL-6 levels were correlated with variations in DLCO [40]. Here, MUC1 is linked to idiopathic pulmonary fibrosis.